The Patent Finder

Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof

Abelzeta Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 4 of these applications claim priority to application 16/877,069, filed May 18, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 11,207,349Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
In force
 · High confidence
Abelzeta Inc.In force
High confidence
US 11,439,665Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Application Thereof
In force
 · High confidence
Abelzeta Inc.In force
High confidence
US 11,633,430Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
In force
 · High confidence
Abelzeta Inc.In force
High confidence
US 12,448,432Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
In force
 · High confidence
Abelzeta Inc.In force
High confidence
US 12,753,221Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
In force
 · High confidence
Abelzeta Inc.In force
High confidence
Application 17/911,502Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Application Thereof
Pending
Not granted
Abelzeta Inc.PendingNot granted
Application 17/911,524Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Applications Thereof
Abandoned
Abandoned Aug 22, 2026
Abelzeta Inc.AbandonedAbandoned Aug 22, 2026
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Abelzeta Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited